Artivion, Inc. AORT
Medical/Dental Instruments · data as of November 13, 2026
Artivion, Inc. (AORT) is a healthcare company listed in the US with a market value of about $932M. In the twelve months to September 30, 2026 it had revenue of $482M and net income of -$18M, a net margin of -3.7%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 12% a year, a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.
About Artivion
Artivion is listed in the US and classified in medical/dental instruments. Revenue went from $145M in 2014 to $441M in 2025, growth of about 10.7% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 18% over three years (dilution for shareholders). It spends 7% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $482M | $441M | $389M | $354M | $314M | $299M | $253M | $276M | $263M | $190M | $180M |
| Net income | -$18M | $10M | -$13M | -$31M | -$19M | -$15M | -$17M | $2M | -$3M | $4M | $11M |
| Free cash flow | -$44M | $839000 | $11M | $9M | -$16M | -$16M | $5M | $8M | $4M | $4M | $14M |
| EPS (diluted) | $-0.36 | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.32 |
| Net margin | -3.7% | 2.2% | -3.4% | -8.7% | -6.1% | -5.0% | -6.6% | 0.6% | -1.1% | 1.9% | 6.0% |
| ROIC | — | 3.2% | 4.8% | 0.7% | 0.8% | 1.0% | 0.4% | 2.6% | 1.5% | 1.3% | 4.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $38.47, 101% above the current price; targets range from $30.00 to $45.00; the consensus rating is “Strong buy”; expected EPS is $0.37 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Artivion stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Artivion pay a dividend?
Not currently.
Is Artivion a good stock to buy?
We do not give buy or sell advice. Artivion scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.